Observational studies demonstrate aspirin use after diagnosis of colorectal cancer, particularly tumors with mutated PIK3CA, improves outcomes.
However, randomized controlled trial data are lacking.
Here, we discuss the SAKK41/13 adjuvant aspirin randomized controlled trial results in context of other adjuvant aspirin trials and emerging data on potential mechanisms of action.
